Clinical Trials on Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements in Norway

Total 2 results

Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

United States, China, Poland, Israel, Canada, Chile, Czechia, Estonia, France, Greece, Italy, Korea, Republic of, Norway, Spain, Sweden, Thailand, Turkey
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)

Relapsed or Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Austria, Belgium, France, Ireland, Italy, Poland, Spain, United Kingdom

3

Subscribe